Rlam 1 mg delivers immediate-release alprazolam, an intermediate-onset, high-potency triazolo-substituted benzodiazepine derivative. Commonly prescribed for rapid-onset symptom control in acute panic attacks and severe anxiety episodes, this 1 mg strength provides an intermediate therapeutic titration tier between initial starting regimens (0.25 mg to 0.5 mg) and higher maintenance doses required for refractory panic pathology.<\/p>\n
Clinical Profile & Physical Presentation<\/b><\/p>\n Active Pharmaceutical Ingredient:<\/b> Alprazolam (1 mg por comprimido).<\/p>\n<\/li>\n Dosage Form & Appearance:<\/b> Compressed, immediate-release oral tablets, typically formulated as round, light-blue or white tablets with a central score line on one face to enable half-dose (0.5 mg) titration, and debossed with product identifiers (such as “RLAM 1”).<\/p>\n<\/li>\n Manufacturing Excipients:<\/b> Compressed with standard pharmaceutical excipients including microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal anhydrous silica, and approved colorants (such as FD&C Blue No. 2 lake).<\/p>\n<\/li>\n<\/ul>\n Pharmacodynamics & Mechanism of Action<\/b><\/p>\n Allosteric GABA Modulation:<\/b> Selectively binds to a specific regulatory pocket at the interface between the $\\alpha$<\/span> ($\\alpha_1, \\alpha_2, \\alpha_3, \\text{or } \\alpha_5$<\/span>) and $\\gamma_2$<\/span> subunits of the pentameric $\\text{GABA}_\\text{A}$<\/span> receptor-chloride channel complex.<\/p>\n<\/li>\n Chloride Influx & Hyperpolarization:<\/b> Binds without directly activating the receptor pore; instead, it increases the opening frequency of the chloride channel in response to endogenous gamma-aminobutyric acid ($\\text{GABA}$<\/span>). The resulting inward chloride flux hyperpolarizes post-synaptic neuronal membranes, dampening excitability across the amygdala, hippocampus, and the ascending reticular activating system.<\/p>\n<\/li>\n Triazolo Ring Characteristics:<\/b> The incorporation of a fused triazole ring onto the basic benzodiazepine framework confers both high binding affinity and relatively rapid metabolic clearance compared to classic long-acting 2-keto benzodiazepines (such as diazepam).<\/p>\n<\/li>\n<\/ul>\n Pharmacokinetics & Biotransformation<\/b><\/p>\n Absorption & Bioavailability:<\/b> Readily and completely absorbed from the gastrointestinal tract following oral administration, demonstrating an absolute bioavailability of 80% to 90%.<\/p>\n<\/li>\n Peak Plasma Concentration ($T_{\\max}$<\/span>):<\/b> Peak plasma concentrations ($C_{\\max}$<\/span>) are reached rapidly, typically within 1 to 2 hours post-ingestion.<\/p>\n<\/li>\n Distribution & Protein Binding:<\/b> Approximately 80% plasma protein-bound (primarily to serum albumin), with an apparent volume of distribution ($V_d$<\/span>) averaging 0.8 to 1.3 L\/kg.<\/p>\n<\/li>\n Hepatic Clearance:<\/b> Metabolized predominantly by hepatic cytochrome P450 3A4 (CYP3A4). Biotransformation yields two primary hydroxylated metabolites: $\\alpha$<\/span>-hydroxyalprazolam (exhibiting roughly half the bioactivity of the parent compound) and 4-hydroxyalprazolam, both present at very low circulating levels.<\/p>\n<\/li>\n Elimination:<\/b> Mean terminal elimination half-life ranges from 11 to 15 hours in healthy adults. Clearance proceeds largely through renal elimination of glucuronide conjugates.<\/p>\n<\/li>\n<\/ul>\n Prescribing Guidelines & Administration Protocols<\/b><\/p>\n Administration:<\/b> Administered orally with or without food. Tablets may be split along the functional score line if directed by a physician for individualized titration.<\/p>\n<\/li>\n Duration of Therapy:<\/b> Recommended for short-term acute intervention. Long-term continuous administration is generally discouraged due to the predictable emergence of pharmacological tolerance and physiological dependence.<\/p>\n<\/li>\n Tapering Protocols:<\/b> Therapy should never be discontinued abruptly. Discontinuation requires a gradual, structured dosage reduction (e.g., decrements of no more than 0.5 mg every three days) under strict medical supervision to prevent severe rebound anxiety and acute autonomic withdrawal reactions.<\/p>\n<\/li>\n<\/ul>\n Important Safety Information & Boxed Warnings<\/b><\/p>\n Concomitant Use with Opioids:<\/b> Concurrent administration of benzodiazepines with opioids significantly elevates the risk of profound sedation, life-threatening respiratory depression, coma, and mortality. Co-prescribing should be reserved strictly for cases where alternative treatment strategies are inadequate.<\/p>\n<\/li>\n Abuse, Misuse, and Addiction:<\/b> Alprazolam is a Schedule IV controlled substance carrying high potential for misuse, physical dependence, and diversion. Misuse frequently involves co-ingestion with other central nervous system depressants or alcohol, substantially multiplying fatal overdose risks.<\/p>\n<\/li>\n Dependence and Withdrawal Syndromes:<\/b> Chronic use leads to physiological neuroadaptation. Abrupt discontinuation can precipitate severe, life-threatening withdrawal complications, including generalized tonic-clonic seizures, status epilepticus, delirium tremens, hallucinations, and severe tremors.<\/p>\n<\/li>\n Contraindications:<\/b> Contraindicated in individuals with known hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, severe respiratory insufficiency, sleep apnea syndrome, or severe hepatic impairment. Concomitant administration with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) is contraindicated.<\/p>\n<\/li>\n<\/ul>\n\n \n
\n
\n
\n
\n